Post-progression outcomes of NSCLC patients with PD-L1 expression &#x2265; 50% receiving first-line single-agent pembrolizumab in a large multicentre&#xA0;real-world study

Lung, Respiratory and Thoracic Cancer

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression

Ann Oncol.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RI, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM

doi: 10.1093/annonc/mdz288.

Lung, Respiratory and Thoracic Cancer

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Ann Oncol.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM

doi: 10.1093/annonc/mdz288.

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Central Nervous System TumorsLung, Respiratory and Thoracic Cancer

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Lung, Respiratory and Thoracic Cancer

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C

doi: 10.1001/jamaoncol.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status

★ 1 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

doi: 10.1016/j.ejca.2020.02.023.

Lung, Respiratory and Thoracic Cancer

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Lancet Oncol.

Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R Reck M

doi: 10.1016/

Lung, Respiratory and Thoracic Cancer

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland

Swiss Med Wkly.

Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M

doi: 10.4414/smw.2019.20170.

Genitourinary Cancer

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

J Clin Oncol.

Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, Fang X, Godwin JL, Frenkl TL, Homet Moreno B, de Wit R, Plimack ER

doi: 10.1200/JCO.19.01213.

Oncology · Hematology

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Related content

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Recent Developments in Metastatic Breast Cancer

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer